Welcome to LookChem.com Sign In|Join Free

CAS

  • or
PDE-9, also known as Phosphodiesterase 9, is a type of enzyme that plays a crucial role in cellular functions by breaking down cyclic guanosine monophosphate (cGMP), a molecule that transmits signals inside the cell. It has been found in high levels in the brain, indicating its involvement in various neurological processes.
Used in Pharmaceutical Industry:
PDE-9 is used as a therapeutic target for the development of inhibitors that could potentially treat neurological and psychological disorders such as Alzheimer's disease and schizophrenia. The inhibition of PDE-9 may help in modulating the levels of cGMP, which is involved in signal transduction pathways related to these disorders.
Used in Immunology Research:
PDE-9 is used as a potential target for the treatment of autoimmune diseases. Its involvement in the regulation of the immune system suggests that modulating its activity could help in managing immune responses in conditions like autoimmune disorders.
Used in Neurological Research:
PDE-9 is used as a subject of study in understanding the molecular mechanisms underlying various neurological processes. By investigating the role of PDE-9 in the brain, researchers aim to uncover its potential implications in the development of new therapeutic strategies for neurological disorders.

1082743-70-1

Post Buying Request

1082743-70-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1082743-70-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1082743-70-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,2,7,4 and 3 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1082743-70:
(9*1)+(8*0)+(7*8)+(6*2)+(5*7)+(4*4)+(3*3)+(2*7)+(1*0)=151
151 % 10 = 1
So 1082743-70-1 is a valid CAS Registry Number.

1082743-70-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-[(3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl]-1-(oxan-4-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-one

1.2 Other means of identification

Product number -
Other names CS-0328

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1082743-70-1 SDS

1082743-70-1Relevant articles and documents

Design and discovery of 6-[(3 s,4 s)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-1-(tetrahydro-2 h -pyran-4-yl)-1,5-dihydro-4 h -pyrazolo[3,4- d ]pyrimidin-4-one (PF-04447943), a selective brain penetrant pde9a inhibitor for the treatment of cognitive disorders

Verhoest, Patrick R.,Fonseca, Kari R.,Hou, Xinjun,Proulx-Lafrance, Caroline,Corman, Michael,Helal, Christopher J.,Claffey, Michelle M.,Tuttle, Jamison B.,Coffman, Karen J.,Liu, Shenpinq,Nelson, Frederick,Kleiman, Robin J.,Menniti, Frank S.,Schmidt, Christopher J.,Vanase-Frawley, Michelle,Liras, Spiros

, p. 9045 - 9054 (2013/01/15)

6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl] -1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943) is a novel PDE9A inhibitor identified using parallel synthetic chemistry and structure-based drug design (SBDD) and has advanced into clinical trials. Selectivity for PDE9A over other PDE family members was achieved by targeting key residue differences between the PDE9A and PDE1C catalytic site. The physicochemical properties of the series were optimized to provide excellent in vitro and in vivo pharmacokinetics properties in multiple species including humans. It has been reported to elevate central cGMP levels in the brain and CSF of rodents. In addition, it exhibits procognitive activity in several rodent models and synaptic stabilization in an amyloid precursor protein (APP) transgenic mouse model. Recent disclosures from clinical trials confirm that it is well tolerated in humans and elevates cGMP in cerebral spinal fluid of healthy volunteers, confirming that it is a quality pharmacological tool for testing clinical hypotheses in disease states associated with impairment of cGMP signaling or cognition.

AMINO-HETEROCYCLIC COMPOUNDS

-

Page/Page column 37, (2009/02/11)

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formul

AMINO-HETEROCYCLIC COMPOUNDS

-

, (2009/01/20)

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formul

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1082743-70-1